Soleus Capital Management, L.P. Relmada Therapeutics, Inc. Transaction History

Soleus Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$34.42 - $43.78 $237,498 - $302,082	-6,900 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$31.59 - $49.98 $129,519 - $204,918	-4,100 Reduced 37.27%	6,900 $308,000
Q1 2020 May 15, 2020	BUY	$23.78 - $50.12 $261,580 - $551,320	11,000 New	11,000 $375,000

8.32M

364K

46.5K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.